SPRED1 and acute promyelocytic leukemia: In non-APL, significantly lower EFS (p = 0.026; Figure 5A) and PFS (p = 0.041; Figure 5B) rate at 2 years were demonstrated in the group with lower SPRED1 mRNA; however, there was no significant difference of OS of non-APL patients with lower or higher SPRED1 mRNA (p = 0.348; Figure 5C).